It has been postulated that the presence of mutated RAS and BRAF in follicular thyroid cancer (FTC) and papillary thyroid cancer (PTC), respectively, in association with later acquired alterations in TP53 and mTOR pathway, might be responsible for this process of dedifferentiation [2,24,25]. Here, BRAF is linked to thyroid cancer, nonmedullary, 2.